Endorectal MRI for prediction of tumor site, tumor size, and local extension of prostate cancer

Nakashima, Jun; Tanimoto, Akihiro; Imai, Yutaka; Mukai, Makio; Horiguchi, Yutaka; Nakagawa, Ken; Oya, Mototsugu; Ohigashi, Takashi; Marumo, Ken; Murai, Masaru

doi:10.1016/j.urology.2004.02.036

Cited by 145 publications

(110 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These findings of our study suggest that MRI, with its highresolution, cannot be replaced, especially for T-staging, and thus continues to have a role in the diagnostic assessment of prostate cancer -either when used alone or when used in combination with another modality in fusion imaging. In recent years, prostate cancer MRI has developed from the use of endorectal coil techniques with accuracies, sensitivities, and positive predictive values (PPV) of 79.8%, 85.3%, and 92.6% for cancers larger than 1 cm and of 24.2%, 26.2%, and 75.9% for cancers less than 1 cm in diameter and an accuracy of 68% for the differentiation of T2 and T3 prostate cancer to the use of body coils and multiparametric pulse sequences [14,15]. Multiparametric imaging offers the advantage of providing valid additive information on cancer extent outside the prostate, as for instance shown in a prospective study of Lista et al [16].…”

Section: Discussionmentioning

confidence: 99%

Usefulness of Ga-68 HBED-CC PSMA PET/CT for Tumor Staging in the Initial Diagnostic Assessment of Prostate Cancer

Schreiter¹,

Gericke²

2016

J Nucl Med Radiat Ther

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Usefulness of Ga-68 HBED-CC PSMA PET/CT for Tumor Staging in the Initial Diagnostic Assessment of Prostate Cancer

Schreiter¹,

Gericke²

2016

J Nucl Med Radiat Ther

View full text Add to dashboard Cite

“…Combining different imaging techniques has been shown to significantly increase the accuracy of MRIcalculated tumor volume 15,16 . A safety margin of 5mm is considered in prostate cancer.…”

Section: Tumor Volumementioning

confidence: 99%

Prostate cancer - the role of magnetic resonance imaging

Mocikova

Babela²,

Balaz³

2012

BIOMED PAP

View full text Add to dashboard Cite

Background. This article reviews the potential of magnetic resonance imaging (MRI) in prostate cancer diagnosis. Methods. Systematic scan of Pubmed, Ovid, Medline, Elsevier search engines was used, additional information was found through bibliographic review of relevant articles. Results. Substantial progress has been made in the imaging of prostate cancer in MR imaging, as well as in advanced MR spectroscopy. Conclusions. MRI is a non-invasive and direct imaging modality useful for cancer staging, therapy response, detection of recurrence and guided biopsy in previous negative biopsies. MRI with 3.0 T system, whole-body MRI, dynamic contrast enhanced MRI, diffusion-weighted imaging (DWI) and MR spectroscopy (MRS) have improved tumor staging, assessment of tumor volume, aggressiveness or recurrence. Implementation of endorectal/phased array superficial MRI findings on 1.5 or 3.0 T systems into nomograms for prostate pretreatment prediction is warranted. Surface phasedarray coil MRI accurately defines prostate cancer with elevated risk of extraprostatic disease.

show abstract

“…The results of the Radiology Diagnostic Oncology Group-sponsored prospective randomized trial (1) found no benefit for pelvic magnetic resonance imaging (MRI) performed with a body coil over transrectal ultrasound (TRUS) for staging men with clinically localized prostate cancer. Single-institution studies (2)(3)(4) performing MRI with an endorectal (e) coil have shown promise in men with palpable and intermediate-or high-risk disease where the overall accuracy of these modalities approximate 80% for the identification of occult extraprostatic disease. However, for the majority of men who present based on serial prostate-specific antigen (PSA) screening with nonpalpable disease, which imaging modality, if any, provides reliable information about the local extent of the disease remains an open question.…”

Section: Introductionmentioning

confidence: 99%

Tumor Volume Changes on 1.5 Tesla Endorectal MRI During Neoadjuvant Androgen Suppression Therapy for Higher-Risk Prostate Cancer and Recurrence in Men Treated Using Radiation Therapy Results of the Phase II CALGB 9682 Study

D’Amico

Halabi

Tempany

et al. 2008

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

Purpose-We prospectively determined whether the change in tumor volume (TV) during 2 months of neoadjuvant androgen suppression therapy (nAST) measured using conventional 1.5 Tesla endorectal magnetic resonance imaging (eMRI) was associated with the risk of recurrence after radiation (RT) and 6 months of AST. 1997 and 2001, 180 men with clinical stage T1c-T3cN0M0 adenocarcinoma of the prostate were registered. Fifteen were found to be ineligible and the institutional MR radiologist could not assess the TV in 32, leaving 133 for analysis. Multivariable Cox regression analysis was used to assess whether a significant association existed between eMRIdefined TV progression during nAST and time to recurrence adjusting for prostate-specific antigen (PSA) level, Gleason score (8 to 10 or 7 vs. 6 or less) and stage (T3 vs. T1-2). Patients and Methods-BetweenResults-After a median follow up of 6.7 years and adjusting for known prognostic factors, there was a significant increase in the risk of PSA failure (HR, 2.3 [95% CI, 1.1-4.5; p = 0.025) in men with eMRI-defined TV progression during nAST. Specifically, adjusted estimates of PSA failure were significantly higher (p = 0.032) in men with, compared with men without, eMRI-defined TV progression reaching 38% vs. 19%, respectively, by 5 years. Conclusion-Eradicating

show abstract

Endorectal MRI for prediction of tumor site, tumor size, and local extension of prostate cancer

Cited by 145 publications

References 25 publications

Usefulness of Ga-68 HBED-CC PSMA PET/CT for Tumor Staging in the Initial Diagnostic Assessment of Prostate Cancer

Usefulness of Ga-68 HBED-CC PSMA PET/CT for Tumor Staging in the Initial Diagnostic Assessment of Prostate Cancer

Prostate cancer - the role of magnetic resonance imaging

Tumor Volume Changes on 1.5 Tesla Endorectal MRI During Neoadjuvant Androgen Suppression Therapy for Higher-Risk Prostate Cancer and Recurrence in Men Treated Using Radiation Therapy Results of the Phase II CALGB 9682 Study

Contact Info

Product

Resources

About